1Agop Y. Bcl-2 antisense ( oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the oblimersen melanoma study group[ J ]. JCO, 2006, 24 (29) :4738 - 4745.
2Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma [ J ]. Proc Natl Acad Sci U S A, 2003, 100:8372- 8377.
3Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients[J]. Proc Natl Acad Sci U S A, 2003, 100:4712 -4717.
4Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anticytotoxic T-lymphocyte antigen-4 [ J]. J Clin Oncol, 2005, 23:6043 -6053.
5Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase Ⅰ trial of a fully human anticytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages Ⅲ and Ⅳ melanoma[J]. J Clin Oncol, 2005, 23:741 -750.
6Ribas A, Camacho LH, I.opez-Berestein G, et al. Antitumor activity in melanoma and antiself responses in a phase Ⅰ trial with the anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206 [ J ]. J Clin Oncol, 2005, 23:8968 - 8977.
7Maker AV, Phan GQ, Attia P, et al. Tumor regression and auto- immunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase Ⅰ/Ⅱ study [J]. Ann Surg Oncol, 2005, 12:1005 -1016.
8Blansfield JA, Beck KE, Tran K, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer[ J ]. J Immunother, 2005, 28 : 593-598.
9Moschos SJ, Edington HD, Land SR, et al. Neoadjuvant treatment of regional stage Ⅲ B melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses [ J ]. J Clin Oncol, 2006, 24:3164-3171.
10Kirkwood JM, Strawderman MH, Emstoff MS. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684[ J]. J Clin Oncol, 1996, 14(1 ):7- 17.
